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Targeting of numerous transmembrane proteins to the cell surface is thought to depend on their recognition
by cargo receptors that interact with the adaptor machinery for anterograde traffic at the distal end of the
Golgi complex. We report here on consortin, a novel integral membrane protein that is predicted to be intrin-
sically disordered, i.e. that contains large segments whose native state is unstructured. We identified consor-
tin as a binding partner of connexins, the building blocks of gap junctions. Consortin is located at the
trans-Golgi network (TGN), in tubulovesicular transport organelles, and at the plasma membrane. It directly
interacts with the TGN clathrin adaptors GGA1 and GGA2, and disruption of this interaction by expression of
a consortin mutant lacking the acidic cluster–dileucine (DXXLL) GGA interaction motif causes an intracellu-
lar accumulation of several connexins. RNA interference-mediated silencing of consortin expression in HeLa
cells blocks the cell surface targeting of these connexins, which accumulate intracellularly, whereas partial
depletion and redistribution of the consortin pool slows down the intracellular degradation of gap junction
plaques. Altogether, our results show that, by studying connexin trafficking, we have identified the first
TGN cargo receptor for the targeting of transmembrane proteins to the plasma membrane. The identification
of consortin provides in addition a potential target for therapies aimed at diseases in which connexin traffic is
altered, including cardiac ischemia, peripheral neuropathies, cataracts and hearing impairment.
Sequence accession numbers. GenBank: Human CNST cDNA, NM_152609; mouse Cnst cDNA, NM_146105.
INTRODUCTION
Protein traffic along the secretory pathway involves the recog-
nition of specific sorting signals by specialized machinery at
multiple steps, from the endoplasmic reticulum to other intra-
cellular compartments or the plasma membrane (1). Many
sorting signals (e.g. peptide motifs, signal patches, post-
translational modifications. . .) mediate the direct interaction
of the protein to be sorted with the adaptor proteins required
for the formation of vesicular or tubular transport carriers
(2,3). Sorting of proteins lacking such signals relies instead
on the binding of the protein to a specific cargo receptor, i.e.
a transmembrane protein that simultaneously interacts with
the protein to be sorted and with the adaptor machinery. The
best-characterized example of cargo receptors is provided by
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the sorting of lysosomal acidic hydrolases. These soluble
enzymes, labeled with mannose-6-phosphate (M6P) groups,
are recognized at the trans-Golgi network (TGN) by trans-
membrane M6P receptors, which interact on the cytosolic
side of the membrane with the adaptor protein 1 (AP1)
complex (4) and the Golgi-localized, gamma-ear containing,
ADP-ribosylation-factor binding (GGA) adaptors (5,6) to
promote transport out of the TGN. After releasing their
cargo in endosomes, the M6P receptors are recycled back to
the TGN for further rounds of trafficking (6).
Although the sorting signals for targeting of transmembrane
proteins to the plasma membrane have begun to be elucidated
(1,3), the identities of the cargo receptors required for the traf-
ficking of such proteins remain unknown (7). In this work, we
focused on the plasma membrane targeting of connexins, the
major constituents of the intercellular channels that compose
vertebrate gap junctions. Connexins are non-glycosylated,
integral membrane proteins with four membrane-spanning
segments, one cytosolic and two extracellular loops, and N-
and C-termini exposed to the cytosol (8,9). The connexin
family comprises 22 members in humans and 19 in mice,
with molecular weight from 25 to 62 kDa (10–12). All con-
nexins enter the secretory pathway and are delivered to the
plasma membrane by way of the endoplasmic reticulum and
the Golgi complex. Along this route, connexin monomers
assemble into hexameric connexons. There is also evidence
for an alternative, Golgi-independent pathway for the delivery
of connexin 26 to the plasma membrane (9,13).
Members of the connexin family underlie human pathologi-
cal conditions as diverse as hearing impairment, cataracts, per-
ipheral neuropathies, genodermatoses, oculodentodigital
dysplasia or Pelizaeus–Merzbacher-like disease. In fact, the
most prevalent form of inherited non-syndromic hearing
impairment, DFNB1, is caused by mutations affecting the
genes that encode connexins 26 (Cx26) and 30 (Cx30). To
better understand the pathologic process in DFNB1 hearing
impairment, we tried to identify ligands shared by these two
connexins. By using a yeast two-hybrid approach, we ident-
ified consortin, a novel ubiquitously-expressed, connexin-
binding protein. Our results show that consortin, named after
its role in the intracellular sorting of connexins, acts as a
TGN receptor involved in connexin targeting to the plasma
membrane and recycling from the cell surface.
RESULTS
Identification of consortin, a predicted intrinsically
disordered protein
We sought to identify ligands common to Cx26 and Cx30, the
major connexins expressed in the inner ear, by using the yeast
two-hybrid technique. All previous attempts to identify
connexin-binding proteins by means of such technique had
relied on using either the cytosolic loop or the C-terminal
tail of connexins as baits, instead of the full-length protein
(14–16). Indeed, it was felt that the transmembrane segments
of connexins would prevent the translocation of the full-length
bait polypeptide to the yeast nucleus (14), resulting in the
failure of the screen. Since the cytosolic loops and the
C-terminal tails are the most variable segments of connexins
(9,10), such strategy resulted in the identification of ligands
specific of a single connexin species. Instead, we used full-
length Cx26 and Cx30 as baits to screen a mouse cDNA
library obtained from the sensory areas of the vestibule, the
balance organ of the inner ear (17). In the Cx26 and Cx30
assays we identified, respectively, 18 and 6 independent posi-
tive clones that corresponded to the product of
9630058J23Rik, an 11-exon gene. RT–PCR analyses indi-
cated that this gene was expressed in all mouse tissues we
tested (inner ear, eye, brain, heart, lung, liver, kidney, testis
and muscle), which suggests that the cognate protein, which
we termed consortin, is ubiquitous. 5’-RACE experiments
indicated that the gene encodes at least two different isoforms:
a short isoform (422 amino acids, 45.3 kDa), encoded by
exons 8–11; and a long isoform (711 amino acids,
76.8 kDa), encoded by exons 2–11, which includes the
entire short isoform (Fig. 1A).
BLAST database searches showed the existence of consor-
tin gene orthologs in several vertebrate genomes from fish to
mammals, but not in any of the fully sequenced, non-
vertebrate eukaryotic genomes, which suggests that consortin
is limited to vertebrates, as is the connexin family of proteins.
Computer-assisted analysis of the deduced polypeptide
showed that the two consortin isoforms share the same charac-
teristics: (1) a high content of acidic residues (19%), which
results in a substantial negative net charge at physiological
pH; (2) a lack of an amino-terminal signal peptide; and (3)
the existence of a hydrophobic stretch long enough to be a
membrane-spanning segment (reliability 0.86), located near
the C-terminus (Fig. 1A). Topology analyses indicated that
consortin is a type-II membrane protein with a long N-terminal
cytosolic fragment, and a short extracellular (luminal) C-
terminal tail. Consortin bears no significant similarity to any
other protein in the sequence databases. Moreover, screening
of PFAM and SMART databases did not detect any known
sequence motifs that would allow classification of consortin
into any of the already identified protein families. Remark-
ably, different algorithms predicted that 65–76% of consortin
residues are disordered (Fig. 1B). This indicates that consortin
should be considered an intrinsically disordered protein, i.e. a
protein that contains large segments that do not fold spon-
taneously into well-organized globular structures in the
absence of stabilizing interactions.
Consortin is a connexin-binding protein
We tested the ability of consortin to bind Cx26 and Cx30 by
means of glutathione-S-transferase (GST) pulldown assays.
We defined the minimal region of the consortin amino acid
sequence that was required for the interaction with Cx26 and
Cx30 by analyzing the overlap of all independent clones ident-
ified in the 2 yeast two-hybrid assays. Of note, the minimal
interaction region did not include the putative transmembrane
segment of consortin (Fig. 1A). Since this minimal interaction
region was contained within the consortin short isoform
(Fig. 1A), we used a GST-consortin short isoform fusion
protein as bait in pulldown assays.
The recombinant GST-consortin fusion protein purified
from Escherichia coli was able to precipitate all the in vitro-
synthesized mouse connexins that we tested, namely Cx26,
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Cx30, Cx31, Cx32, Cx43 and Cx45 (Fig. 2A). To rule out the
possibility that binding occurred by unspecific hydrophobic
interactions between the transmembrane domain of consortin
and those of connexins, we generated a truncated
GST-consortin fusion protein (GST-consortin-DCter, corre-
sponding to residues 1–362 of the short isoform) that lacked
the putative transmembrane domain and C-terminal segment.
GST-consortin-DCter interacted in pulldown assays with all
in vitro-synthesized connexins previously tested (Fig. 2B).
GST-consortin-DCter was also able to pulldown rat Cx26
from detergent-free lysates of a stably transfected Cx26
HeLa cell line (18) (Fig. 2C). Moreover, we observed that
different monoclonal antibodies directed against Cx43
co-precipitated consortin and Cx43 from extracts of HeLa
cells transiently expressing this connexin (Fig. 2D).
Altogether, the data show that consortin is a binding partner
for all groups of connexins.
We next assayed whether consortin would also bind pan-
nexins, which are gap junction proteins with the same topolo-
gical arrangement than connexins but no amino acid sequence
similarity with them (19,20) and, unlike connexins, are found
in both vertebrates and invertebrates (21). We did not detect
any interaction between in vitro synthesized pannexin 1 and
either GST-consortin or GST-consortin-DCter (Fig. 2E).
Endogenous consortin localizes in the TGN
RT–PCR experiments showed that HeLa cells expressed the
consortin gene (HUGO approved symbol: CNST). To detect
the cognate, endogenously synthesized protein, we raised
rabbit polyclonal antibodies against peptides of human consor-
tin and verified the specificity of the affinity-purified
anti-consortin antibodies by immunoblotting (Fig. 3A), as
well as by immunostaining of HeLa cells that synthesized
myc- or GFP-tagged human consortin, and antigen absorption
assays (our unpublished data).
Immunofluorescence microscopy of untransfected HeLa
cells showed that most endogenous consortin was concen-
trated in a perinuclear region, largely overlapping with the
Golgi complex markers GM130 and p58 (Fig. 3B and C).
The remaining consortin labeling was scattered in a punctate
pattern throughout the cytoplasm and up to the cell membrane
(Fig. 3B and C). We tested the association of endogenous con-
sortin with the Golgi complex by treating HeLa cells with
Golgi-disrupting agents. Expression of the dominant activating
Q71L mutant of human ADP ribosylation factor 1 (ARF1),
which enlarges and vesiculates the Golgi apparatus (22),
caused expansion and disaggregation of the perinuclear con-
sortin staining, overlapping in part with ARF1 Q71L
(Fig. 3D). Furthermore, incubation of HeLa cells with nocoda-
zole or brefeldin A resulted in the loss of the perinuclear local-
ization of consortin (Fig. 3E and F). Remarkably, after
brefeldin A treatment the immunostaining for the TGN inte-
gral membrane protein TGN38 and for consortin entirely
overlap (Fig. 3F), strongly arguing for the TGN localization
(23) of consortin. In contrast, we did not observe
co-localization of consortin with Golgi cisternal markers
(GM130, p58) in brefeldin A-treated cells.
Immunoelectron transmission microscopy detected
endogenous consortin in tubulo-vesicular structures on the
trans side of the Golgi apparatus (Fig. 4A and B) as well as
in tubulo-vesicular organelles throughout the cytoplasm of
HeLa cells (Fig. 4B–D), consistently with the immunofluores-
cence data. Occasional vesicles were seen to fuse with the
plasma membrane (Fig. 4E), where sizable levels of consortin
were immunolabeled (Fig. 4B, D and E). These results suggest
that consortin may traffic between the TGN and the plasma
membrane, along the secretory pathway.
Figure 1. Consortin is a disordered integral membrane protein. (A) Structure of mouse consortin short and long isoforms, showing the position of the predicted
transmembrane segment (blue bar, residues 652–669 in the long isoform) and of the DDSDLL sequence (green, residues 557–562 in the long isoform) for
interaction with the monomeric GGA (consensus DXXLL) and tetrameric AP-1, AP-2 and AP-3 adaptors [consensus (D/E)XXXL(L/I)]. The regions for
binding to Cx26 (residues 521–711 in the long isoform) and Cx30 (residues 503–631 in the long isoform), deduced from the overlap of consortin yeast two-
hybrid clones interacting with the connexin baits, are indicated. (B) Prediction of disordered regions in consortin by the IUPred algorithm, showing the positions
of the transmembrane domain and connexin-interaction region (residues 521–631). The short C-terminal tail of consortin is well structured and likely to form a
globular domain. In contrast, the putatively cytosolic, N-terminal segment of consortin, which includes the connexin-interacting region, is highly disordered. This
structural arrangement is conserved in all full-length consortin orthologs known.
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Consortin binds to the TGN adaptors GGA1 and GGA2
To assess the cellular role of consortin, we searched for its
binding partners by means of a yeast two-hybrid screening of
our inner ear cDNA library. We used the short isoform of con-
sortin as bait in order to find ligands that were common to both
the long and short consortin isoforms. In our screening we
identified single clones of the TGN adaptors GGA1 and
GGA2. GST-pulldown experiments confirmed that GGA1
and GGA2 indeed bind to consortin in vitro (Fig. 5A and C).
Moreover, consortin and the two GGA adaptors are located
in the same subcellular compartments (Fig. 5B and D).
The GGA proteins are monomeric clathrin adaptors that
mediate cargo sorting and vesicle formation at the TGN
(24–27). GGAs consist of four domains arranged in tandem:
a VHS domain, which interacts with cargo proteins or cargo
receptors (e.g. M6P receptors, sortilin) to be sorted; a GAT
domain, which associates with the GTP-bound forms of
ARF1 and ARF3 mediating the recruitment of the GGAs to
TGN membranes; a flexible hinge region that binds to clathrin;
Figure 2. Consortin interacts with connexins both in vitro and in vivo. (A) Pulldown experiments of different in vitro synthesized and radioactively labeled
connexins (Cx26, Cx30, Cx31, Cx32, Cx43 and Cx45) by a batch-purified GST-consortin (short isoform) chimera. For each pulldown assay, three lanes are
shown, corresponding to the relevant in vitro translation reaction (input), a control assay with batch-purified GST (GST), and the assay with the appropriate
GST chimera (GST-consortin). Bands corresponding to putative connexin monomers and hexamers are indicated by arrows and arrowheads, respectively.
Note that the hexamer band is consistently enriched in the GST-consortin pulldown lane, compared with the input lane. (B) In vitro synthesized, radioactively-
labeled Cx26 and Cx30 were pulled down by batch-purified GST-consortin-DCter synthesized in Escherichia coli, which indicates that connexin binding does
not occur through hydrophobic interactions with the putative transmembrane domain of consortin. (C) Pulldown assay of Cx26 from detergent-free lysates of
HeLa-Cx26 cells with GST-consortin (short isoform) and GST-consortin-DCter chimeras synthesized in E. coli. A band corresponding to putative Cx26 hex-
amers, detected with an anti-Cx26 antibody, is observed in the GST-consortin-DCter lane. In contrast, no band was detected in the GST-consortin lane, indicating
that membrane-inserted Cx26 does not interact with the short isoform of consortin. This may be due to a blockade by the transmembrane segment and C-terminal
tail of non-membrane-inserted consortin, which are not part of the minimal connexin-interaction region of consortin. (D) Immunoprecipitation of Cx43 from
extracts of HeLa cells transiently transfected with expression plasmid pNTCx43. Extracts were immunoprecipitated with an irrelevant monoclonal antibody
(anti-myc), anti-Cx43 monoclonal antibody P2D12, or a mixture of anti-Cx43 monoclonal antibodies IF1 and CT1. Bands corresponding to Cx43 and the
short isoform of consortin are detected by immunoblotting in the immunoprecipitates obtained with the anti-Cx43 antibodies, but not in those obtained with
the irrelevant antibody, indicating that consortin and Cx43 co-precipitate and may interact in vivo. (E) Escherichia coli-synthesized, batch-purified,
GST-consortin and GST-consortin-DCter do not pulldown in vitro synthesized pannexin 1 (Panx1).
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and a GAE domain that recognizes accessory proteins of the
trafficking machinery (28). In our two-hybrid assay, the
consortin-interacting fragments of GGA1 (residues 1–260)
and GGA2 (residues 1–278) spanned the full-length VHS
domain. This domain binds to an ‘acidic cluster–dileucine’
peptide motif (consensus DXXLL, close to a phosphorylatable
serine residue) located in the cytoplasmic tails of proteins
sorted by the GGA adaptors (5,29–31). Examination of the
consortin sequence with different motif-screening algorithms
detected one DDSDLL sequence (residues 571–576) match-
ing this consensus (Fig. 1A), and conserved in all consortin
orthologs. Notably, the same site also matches the consensus
sequence (D/E)XXXL(L/I) recognized by the tetrameric
AP1, AP2 and AP3 adaptor complexes (2) (Fig. 1A).
In view of the TGN and plasma membrane localization of
consortin, of its ability to bind to connexins, and of its inter-
actions with the GGA1 and GGA2 adaptors, we hypothesized
that consortin might play a role in the targeting of connexins to
the plasma membrane. To test this hypothesis, we generated
by site-directed mutagenesis an expression plasmid coding
for a short consortin isoform in which the DSDLL sequence
had been replaced with NSDAA. This substitution is known
to inactivate the DXXLL sorting signal (2). NSDAA-consortin
retained the ability to bind connexins in GST-pulldown exper-
iments (Fig. 6A). Transfection of HeLa cells producing Cx26
or Cx45-eGFP with a control expression plasmid coding for
wild-type consortin had no effect on the plasma membrane tar-
geting of either connexin, which formed immunostained
plaques at cell–cell contacts (Fig. 6B). In contrast, transfec-
tion of connexin-expressing HeLa cells with the plasmid
encoding NSDAA-consortin resulted in a striking intracellular
accumulation of both Cx26 and Cx45 (Fig. 6C). These results
imply that consortin recruits TGN adaptors that are required
for the intracellular trafficking of connexins.
We did not observe any intracellular accumulation of
connexins when Cx26- or Cx45-eGFP-expressing cells were
Figure 3. Subcellular localization of consortin in the Golgi apparatus. (A)
Detection of consortin by an affinity-purified polyclonal antibody in lysates
of untransfected HeLa cells (HeLa) or HeLa cells transiently transfected
with a GFP-tagged human consortin construct (HeLa/consortin-GFP). Exogen-
ously expressed consortin-GFP and endogenously expressed consortin are
indicated by arrows. The lower molecular mass bands detected by the antibody
(asterisks) may correspond to isoforms generated by translation started from a
hypothetical internal ribosomal entry site or by post-translational processing.
(B, C) Confocal microscopy images of HeLa cells stained for endogenous con-
sortin (green) and the Golgi apparatus markers (red) GM130 (B) and p58 (C).
(D) Modification of the distribution of consortin (green) in HeLa cells transi-
ently transfected with the dominant negative Q71L mutant of human ARF1
(red). (E, F) Modification of the distribution of consortin in HeLa cells
treated with Golgi-disrupting agents nocodazole (15 mM for 2 h) (E) and bre-
feldin A (5 mM for 45 min) (F); cells were stained for consortin (green) and for
the Golgi markers (red) GM130 (E) or TGN48 (F). Bars, 5 mm.
Figure 4. Endogenous consortin localizes to the Golgi apparatus and the cell
membrane. (A) Immunogold labeling of HeLa cells reveals most consortin in
tubulo-vesicular structures (some pointed by arrowheads) of the TGN, and
rarely in the cisternae of Golgi stacks (double arrowhead). (B) Consortin is
also immunolabeled in tubulo-vesicular structures (white arrowheads) at a dis-
tance from the TGN (black arrowhead), as well as at the plasma membrane
(arrows), mostly at microvilli. (C–E) Consortin-containing tubulo-vesicular
structures (arrowheads) are observed throughout the cytoplasm (C), close to
the plasma membrane (D) and fusing with it (E). Bars, 300 nm (A, B) and
200 nm (C–E).
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transfected with plasmids that encode either of the dominant
negative GGA mutants GGA1 VHS-GAT and GGA2
VHS-GAT, which do not recruit clathrin and thus inhibit
GGA-dependent coat assembly (5,32). This result suggests
that, in addition to the GGAs, consortin may recruit other
adaptors to promote connexin traffic.
Knockdown of consortin expression blocks targeting
of Cx32, Cx43 and Cx45 to the plasma membrane
To confirm the role of consortin in connexin trafficking, we tested
the effect of RNAi-mediated consortin knockdown on the mem-
brane targeting of different connexins. We used two complemen-
tary approaches to reduce consortin expression: transfection of
synthetic short interfering RNAs (siRNAs), and generation of
HeLa cell clones stably expressing microRNA-based short
hairpin RNAs (shRNAs). Both approaches resulted in significant
reduction of the protein levels of consortin and, when combined,
silenced consortin expression (Fig. 7A).
In HeLa cells expressing Cx32, Cx43 or Cx45-eGFP, con-
sortin knockdown by means of different siRNA/shRNA com-
binations induced a dramatic reduction (up to 90%) in the
number of immunostained connexin plaques at cell–cell con-
tacts, compared with control cells treated with non-targeting
siRNAs/shRNAs (Fig. 7B and Supplementary Material,
Table S1). Consortin knockdown also induced a massive intra-
cellular accumulation of Cx32, Cx43 or Cx45-eGFP (Fig. 7C–
E), reminiscent of that observed in cells transfected with a
plasmid coding for NSDAA-consortin (Fig. 6C). Only a
portion of the intracellular connexin localized at the Golgi
complex, as indicated by a partial overlap of connexin and
GM130 stainings (Fig. 7C–E). Consortin knockdown in
HeLa cells expressing Cx26 also led to the intracellular
accumulation of this connexin, but did not significantly alter
the number of connexin plaques at cell–cell contacts (Sup-
plementary Material, Fig. S1 and Table S1).
Partial depletion and redistribution of the cellular
consortin pool increases the size of membrane gap junction
plaques and the number of cytoplasmic annular gap
junctions
We further explored the effects of consortin down-regulation
mediated by shRNA by using immunoelectron microscopy.
In agreement with previous reports (33), no labeling for
Cx43 was detected in untransfected HeLa cells. However, con-
sortin was observed in the Golgi apparatus, in cytoplasmic
vesicles and at the plasma membrane (Supplementary
Material, Table S2). After stable transfection of a Cx43
expression plasmid, HeLa cells featured a similar pattern of
consortin immunostaining, and further showed Cx43 immuno-
labeling, largely predominating as gap junction plaques at
cell–cell contacts (Fig. 8 and Supplementary Material,
Table S2). Analogous observations were made in HeLa-
RNA NT-Cx43 cells, which were stably co-transfected with
expression plasmids coding for Cx43 and non-targeting (NT)
shRNA (Figs 8 and 9, and Supplementary Material,
Figure 5. Consortin interacts with the TGN adaptors GGA1 and GGA2. (A)
GST-pulldown assay of in vitro synthesized GGA1 with the GST-consortin
chimera. (B) Co-localization of consortin (green) with GGA1-myc (red), in
transfected HeLa cells synthesizing this chimeric protein. (C) GST-pulldown
assay of in vitro synthesized GGA2 with GST-consortin. (D) Co-localization
of consortin (green) with endogenous GGA2 (red) in HeLa cells. Bars, 10 mm.
Figure 6. Mutant NSDAA-consortin alters the intracellular traffic of connex-
ins. (A) Pulldown of Cx26, Cx30, Cx43 and Cx45 by GST-NSDAA-consortin.
Bands corresponding to the monomeric form of the indicated connexin and its
putative hexamer are indicated by arrows and arrowheads, respectively. (B) In
HeLa cells expressing either Cx45-eGFP or Cx26, co-expression of wild-type
consortin has no effect on the cell surface display of either connexin, which
formed plaques at intercellular contacts consistent with the presence of gap
junctions (arrowheads). (C) In contrast, expression of the NSDAA-consortin
mutant caused the intracellular accumulation (asterisks) of both Cx45-eGFP
and Cx26. Thus, NSDAA-consortin behaves as a dominant-negative mutant.
White lines outline cell contours, as observed in differential interference con-
trast (DIC) confocal images. Bars, 5 mm.
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Table S2). In contrast, HeLa-shRNA 15-Cx43 cells, stably
co-transfected with expression plasmids coding for Cx43
and CNST-targeting shRNA—which substantially decreases
consortin protein levels (Fig. 7A), featured a different distri-
bution of both consortin and Cx43. The residual consortin
immunolabeling was essentially restricted to the Golgi
Figure 7. Consortin silencing alters the plasma membrane targeting of connexins 32, 43 and 45. (A) Immunoblot of consortin in lysates of HeLa-RNA-NT
(stably expressing a non-silencing control shRNA) and HeLa-shRNA15 cells (stably expressing a consortin-targeting shRNA), after 72 h of siRNA-mediated
consortin knockdown. Ten microgram total cellular protein extract were loaded per lane and b-actin was used as loading control. Maximum consortin silencing
was obtained when combining shRNA stable knockdown with transfection of either CNST-826 or CNST-841 siRNAs. (B) Effect of consorting silencing on the
number of connexin immunolabeled plaques in connexin-expressing HeLa-RNA-NT and HeLa-shRNA15 cells after 72 h of siRNA-mediated consortin knock-
down. In all cases, differences between control and consortin-silenced cells were statistically significant (Supplementary Material, Table S1). (C–E) Effects of
consortin knockdown on connexin distribution in HeLa/RNA-NT and HeLa-shRNA15 cells expressing Cx32 (C), Cx43 (D) or Cx45-eGFP (E) after 72 h of
siRNA transfection. Cells were stained for the appropriate connexin (green) and the Golgi marker GM130 (red), and counterstained with DAPI (blue). Cell
contours are drawn as white lines. Arrowheads indicate immunostained connexin plaques at intercellular contacts. Note the absence of plaques and the
intracellular connexin accumulation (asterisks) in cells undergoing consortin silencing. Bars, 5 mm.
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apparatus (Fig. 8 and Supplementary Material, Table S2), and
Cx43 immunolabeling was seen both at gap junction plaques
on the cell membrane, which were often larger than in
HeLa-Cx43 and HeLa-RNA NT-Cx43 cells and at cytoplasmic
spots (Figs 8 and 9, and Supplementary Material, Table S2).
Immunoelectron microscopy revealed that these spots corre-
sponded to numerous, internalized annular gap junctions
(Fig. 9 and Supplementary Material, Table S2). Cx43 was
also immunolocalized, at much lower levels, within small ves-
icles and TGN elements (Fig. 9 and Supplementary Material,
Table S2), alike those labeled for consortin.
DISCUSSION
We have identified consortin as the first potential TGN cargo
receptor for the sorting and cell surface targeting of transmem-
brane proteins. Consortin interacts both with cargo proteins
(connexins) and with elements of the budding machinery
(GGA adaptor proteins) required for assembly of clathrin-
coated vesicles. Its predominant subcellular localization at
the TGN, as well as in transport vesicles dispersed throughout
the cytoplasm, and the occurrence of consortin-containing ves-
icles fused with the plasma membrane, are consistent with a
role of consortin in TGN-to-plasma membrane secretory
traffic. Moreover, targeted silencing of consortin expression
reduced the number of connexin plaques at the plasma mem-
brane and caused a massive intracellular accumulation of con-
nexins. These alterations are strongly reminiscent of those
observed after down-regulation of proteins involved in
microtubule-dependent transport of connexins to the plasma
membrane (34), and essentially distinct from the disappear-
ance of gap junctions and dramatic reduction in the total cel-
lular amount of connexin caused by knocking down the gap
junction-stabilizing protein drebrin (35), leading us to con-
clude that consortin knockdown blocks the delivery of connex-
ins to the plasma membrane. Consortin thus satisfies all the
requirements for being a dedicated TGN cargo receptor.
It has been postulated that TGN receptors for multipass
transmembrane proteins should detect their oligomeric state,
incorporating only those proteins that are properly folded
and assembled into TGN-derived carriers for delivery at the
cell surface (36). It is thus possible that the interaction
between consortin and connexins actually involves the recog-
nition of their oligomeric state as part of a quality-control
mechanism. The molecular basis of such an interaction may
lie in the intrinsically disordered structure of consortin. The
plasticity of the interaction surfaces of disordered proteins
confers them the ability to adapt to many different partners.
This ‘binding promiscuity’ is a hallmark of proteins such as
chaperones, adaptors and complex assemblers (37). The
finding that consortin interacts with connexins of all classes
(a-, b-, g- or d) is consistent with this view. It is also concei-
vable that as yet unidentified ‘quality-control’ chaperones may
prevent the binding of consortin before connexons are prop-
erly assembled.
Although all connexins reach the plasma membrane by tra-
veling along the secretory pathway, some experiments suggest
Figure 8. The distribution of Cx43 in transfected HeLa cells changes with that of consortin. (A) Immunofluorescence labeling of consortin shows a loose dis-
tribution throughout most of the cytoplasm in HeLa-Cx43 and HeLa-RNA NT-Cx43 cells. In contrast, consortin is mostly restricted to the perinuclear Golgi
apparatus in HeLa-shRNA 15-Cx43 cells (right panel). (B) Immunostaining of Cx43 detects this connexin at small plaques along the membrane interfaces
of HeLa-Cx43 and HeLa-RNA NT-Cx43 cells. In HeLa-shRNA 15-Cx43 cells, Cx43 forms larger plaques at the cell surface and also appears as discrete
spots within the cytoplasm (arrowheads). Bar, 10 mm.
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that Cx26 may also reach the cell surface via a route bypassing
the Golgi complex (9), a property that can be conferred on
Cx32 by a single amino acid substitution that makes Cx32
resemble Cx26 more closely (38). Our results are consistent
with the existence of this parallel route, since knockdown of
consortin expression did not decrease the number of Cx26
plaques at the plasma membrane, unlike what we observed
for Cx32, Cx43 and Cx45. Still, the intracellular accumulation
of Cx26 which we observed after disruption of consortin
function suggests that a substantial proportion of Cx26
travels through the canonical secretory pathway, as reported
(13,39). A route for plasma membrane targeting of integrins
that bypasses the Golgi complex has been reported in
Drosophila at specific developmental stages (40), indicating
that alternative, non-canonical routes may be used for deliver-
ing specific subsets of proteins to the plasma membrane
under certain situations.
Whereas silencing of consortin expression blocked delivery
of connexins to the plasma membrane, partial depletion and
redistribution of the cellular consortin pool unveiled an
additional role for this protein. Gap junction plaques at
HeLa cell interfaces were larger in consortin-depleted cells
than in either wild-type or NT shRNA-expressing control
cells. Under those conditions, cells featured increased
numbers of internalized annular gap junction plaques, which
were seen to undergo progressive degradation. These results
suggest that consortin is implicated in the internalization
and/or intracellular degradation of gap junction plaques.
In cells lacking consortin, the dramatic reduction in these
membrane plaques likely masked this effect, although it may
have contributed to the intracellular connexin accumulation
we observed.
To fulfill its proposed role as a cargo receptor, consortin
must interact simultaneously with its target substrates (con-
nexins) and with coated-vesicle adaptors (Supplementary
Material, Fig. S2). Although the connexin- and GGA-binding
sites lie in the same region of the protein, the observation that
NSDAA-consortin retains the ability to interact with connex-
ins indicates that the two sites are different. It is thus likely
that the two interactions are not mutually exclusive.
The interaction of consortin with the GGA adaptors has two
remarkable features. First, the unusual location of the DXXLL
motif. All previously described type I transmembrane proteins
that bind to the VHS domain of GGAs have their DXXLL
motifs located 1–2 residues away from their C-termini
(2,25). In consortin, a predicted type-II transmembrane
protein, this motif is located within a disordered region in
the middle of the protein, as reported for the autoinhibitory
DXXLL motifs in the unstructured hinge domains of the
GGAs (41). The second feature is the relationship between
consortin-mediated traffic and GGA function. Expression of
dominant-negative GGA mutants lacking the hinge and GAE
domains, unable to recruit clathrin, results in the perinuclear
accumulation of M6P receptors (5,29) and blocks secretion
of soluble proteins whose traffic depends on the GGA
adaptors, like adiponectin (42). However, such truncated
GGAs had no detectable effect on the expression of connexins
at the surface of HeLa cells, whereas expression of a consortin
mutant lacking the motif recognized by the GGAs did induce
an intracellular accumulation of connexins. An attractive
explanation for these apparently discordant results is that con-
sortin may interact with multiple adaptors to promote traffic,
and not exclusively with the GGAs. Accordingly, the mutation
that inactivates the DXXLL sequence of consortin also
destroys an overlapping motif [consensus (D/E)XXXL(L/I)]
recognized by the AP1, AP2 and AP3 adaptors. An internal,
bifunctional sorting signal analogous to that observed in con-
sortin has been reported recently for another transmembrane
GGA ligand, the lipoprotein receptor-related protein LRP9
(43,44). The existence of such bifunctional sorting signals
may be part of a common mechanism for sequential sorting
of cargoes at successive compartments.
Current models of the secretory pathway envision the exist-
ence of a post-TGN, trans-endosomal route to the plasma
membrane, mediated by clathrin-coated vesicles (1). Because
of the interaction of consortin with the GGAs, it is likely
that consortin targets its cargoes to this route. However, this
does not exclude the possibility that consortin might also par-
ticipate in the generation of tubular carriers for direct traffick-
ing of its cargoes from the TGN to the plasma membrane
(45,46). Alternatively, since the GGA adaptors participate in
recycling the GLUT4 transporter from the plasma membrane
(47) and in the traffic of ubiquitinated cargo (48), the inter-
action of consortin with the GGAs might also take place at
steps of the connexin recycling pathway, hence contributing
to both anterograde and retrograde connexin transport.
Figure 9. The intracellular trafficking of gap junction plaques is affected by
consortin redistribution. (A) Immunogold labeling of Cx43 in a typical gap
junction plaque at the membrane interface of two adjacent HeLa-RNA NT
cells stably expressing Cx43. (B) In HeLa-shRNA15 cells stably expressing
Cx43, many annular gap junction plaques are found within the cytoplasm.
(C) In the same cells, much lower levels of Cx43 are detected in Golgi-related
vesicles (arrow) and tubular structures (arrowheads). (D, E) Several of the
annular, Cx43-containing gap junctions found in the cytoplasm of
HeLa-shRNA15 cells show a partial splitting of the two interacting mem-
branes (D, arrow) or lie within lysosomal structures (E). Bar, 170 nm.
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The emergence of specialized TGN sorting mechanisms for
polarized transport and regulated secretion was essential in the
evolution of multicellular animals (7). It is plausible that the
appearance in vertebrates of connexin-mediated intercellular
communication occurred in parallel with that of consortin,
their sorting protein. However, since consortin binds to
several other transmembrane proteins in yeast two-hybrid
assays (our unpublished results), a broader role for consortin
in TGN transport pathways should be envisaged.
Mutations that impair the intracellular trafficking of cell
surface integral membrane proteins, such as receptors, trans-
porters and channels, have been described in many human
inherited disorders. In some instances, the mutation simply
causes an aberrantly folded protein that is retained in the endo-
plasmic reticulum and targeted for degradation. However,
other mutations are known to interfere with later stages of traf-
ficking at the Golgi apparatus or the TGN, as reported for
Cx26 (39), by mechanisms poorly understood. The identifi-
cation of consortin as the first cargo receptor implicated in
the traffic of integral membrane proteins provides a starting
point for unraveling those mechanisms and for designing
novel therapeutic approaches.
MATERIALS AND METHODS
Yeast two-hybrid assays
Screenings of a mouse vestibular cDNA library (17) with
either full-length mouse Cx26, full-length mouse Cx30
or the mouse short consortin isoform were performed by
Hybrigenics.
50 RACE assays
Nested PCR amplification of the 50 end of the mouse consortin
cDNA was performed on a cDNA library generated by the
Marathon method (Clontech) with an oligo-dT primer. The
reverse oligonucleotides used for the specific amplification
of the consortin cDNA were: (1312–1291) 50-CGCCTGCCA
CGCTTACTGCTA-30 (first PCR) and (1111–1091) 50-GCA
GGAACCACCACCAACCTC-30 (nested PCR). PCR products
were cloned into pCR2.1-TOPO (Invitrogen) and sequenced.
Sequence analyses
Prediction of transmembrane domains by different algorithms
and prediction of membrane topology was performed by the
PSORTII (http://psort.nibb.ac.jp) and PredictProtein (http://
www.predictprotein.org) software packages. Search for structural
patterns was carried out with the SMART web server (http://smart.
embl-heidelberg.de). Protein disorder was analyzed with the
IUPred (http://iupred.enzim.hu) (49), DisEMBL (http://dis.
embl.de) (50) and PDisorder (http://www.softberry.com/cgi-bin/
programs/propt/pdisorder.pl) (Softberry Inc.) web servers.
Search for sequence motifs was performed with the MnM (http
://sms.engr.uconn.edu/servlet/SMSSearchServlet) (51) and ELM
(http://elm.eu.org/) (52) algorithms.
Expression constructs
Expression plasmids coding for the GFP-tagged, dominant
negative VHS-GAT GGA1 and GGA2 were provided by J.S.
Bonifacino. The plasmids coding for Cx45-eGFP and rat pan-
nexin 1 were obtained from R. Bruzzone. Mouse cDNAs
encoding the short and long consortin isoforms, the truncated
consortin-DCter isoform, and the GGA1 and GGA2 adaptors
were obtained by RT–PCR of total cochlear mRNA. The full-
length human consortin cDNA was RT–PCR-amplified from
total HeLa cell mRNA. The Cx26, Cx30, Cx31, Cx32, Cx43
and Cx45 coding sequences were amplified by PCR on
mouse 129Sv genomic DNA, since each of them is contained
in a single exon. The sequences of all PCR products were ver-
ified on both strands. cDNAs were cloned into pcDNA3.1V5-
His (Invitrogen; pNT plasmid series, for expression of
untagged proteins and in vitro coupled transcription-
translation), pCMV-tag3B (Stratagene; for fusion to N-
terminal myc tag), pSGC1 (a pCS2þ derivative for fusion to
C-terminal eGFP) and pGEX4T1 (Amersham; for fusion to N-
terminal GST). Mutation of the consortin sequence coding
for the DSDLL motif to NSDAA was carried out with the
QuikChange XL site-directed mutagenesis kit (Stratagene).
Antibodies
Polyclonal antibodies against a mixture of two synthetic pep-
tides of human consortin were raised in rabbits (Covalab).
Peptide sequences were: CNST1 (449–462): NH2-EGKYSQ
AQRKELRL-COOH, and CNST2 (541–555): NH2-NKETE
DYLNSLLEGC-COOH. The specificity of the affinity-
purified antibodies was verified by immunoblotting of total
HeLa cell lysates, immunostaining of HeLa cells that
expressed consortin-myc and consortin-GFP chimeras and
antigen absorption assays. Primary antibodies used in immu-
nofluorescence experiments were: mouse monoclonals
anti-myc epitope (9E10; Santa Cruz), anti-hemagglutinin
epitope (HA-7; Sigma), anti-Cx26 (CX12H10; Zymed),
anti-Cx30 (CX30-8E8; Zymed), anti-Golgi p58 antigen
(58K-9; Sigma), anti-GM130 (BD transduction), anti-GGA2
(BD transduction), anti pan-cytokeratin (C-11; Sigma);
rabbit polyclonals anti-Cx26 (UM214; Zymed), anti-Cx30
(Z-PP9; Zymed), anti-Cx32 (ZMD.193; Zymed), anti-Cx43
(71–0700; Zymed); and goat polyclonal anti-TGN38 (Santa
Cruz). All primary antibodies were used at 1/100 dilutions,
except for the anti-hemagglutinin, anti-GM130 and
anti-TGN38 antibodies, which were used at 1/50 dilutions.
For immunofluorescence detection, we used as secondary anti-
bodies Alexa Fluor 488-conjugated, goat anti-rabbit F(ab’)2
IgG fragment (Molecular Probes), Cy3-conjugated, sheep anti-
mouse IgG (Amersham) and Alexa Fluor 568-conjugated,
donkey anti-goat IgG (Molecular Probes).
GST pulldown assays of cell-free expressed proteins
In vitro synthesis of proteins was carried out with TnT T7
Quick coupled transcription-translation mixtures (Promega)
containing 35S-L-methionine (Amersham). GST-pulldown
assays were performed as described (53).
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GST pulldown assay of HeLa cell-synthesized Cx26
Detergent-free lysates of HeLa cells stably expressing rat Cx26
(HeLa-Cx26, a gift from K. Willecke) (18) were prepared as
reported (54) and cleared of nuclei by centrifugation (24).
The resulting cytoplasmic fractions were incubated for 3 h at
48C in binding buffer (phosphate-buffered saline with 5% gly-
cerol, 5 mM MgCl2 and 0.1% Triton X-100) with GST-
consortin-DCter fusion protein, bound to glutathione-sepharose
beads. After five washes with binding buffer containing 150 mM
NaCl, proteins were separated by denaturing electrophoresis in
NuPAGE 4–12% SDS-polyacrylamide gradient gels (Invitro-
gen) and electrotransferred to nitrocellulose membranes.
Cx26 was detected with rabbit polyclonal anti-Cx26 (Zymed;
0.25 mg ml21) and horseradish-peroxidase-conjugated goat
anti-rabbit antibodies (Amersham), by using the SuperSignal
West Pico enhanced chemiluminescence system (Pierce).
Co-immunoprecipitation
HeLa cells transiently transfected with a Cx43-expressing
plasmid pNTCx43 were grown to confluence, scraped off the
plates, harvested by centrifugation and resuspended in lysis
buffer (20 mM Tris–HCl pH 8.0, 150 mM NaCl, 0.2%
Nonidet P-40, 1 mM DTT, 1X EDTA-free Complete Protease
Inhibitor from Roche). Cell lysates were clarified by a
20-min ultracentrifugation step at 100 000g. Immunoprecipita-
tion was performed by incubating the cleared lysates with any
of three (IF1, CT1, P2D12) anti-Cx43 monoclonal antibodies
(55) bound to Dynabeads Protein G (Invitrogen), as per the
manufacturer’s instructions. After three washes with lysis
buffer, beads were resuspended in NuPAGE LDS sample
buffer (Invitrogen) to release immunoprecipitates. Samples
were separated by denaturing electrophoresis in NuPAGE
4–12% SDS-polyacrylamide gradient gels (Invitrogen) and
electrotransferred to nitrocellulose membranes. Consortin
and Cx43 were detected with rabbit polyclonal antibodies
(anti-consortin, 0.2 mg ml21; anti-Cx43, C6219 Sigma,
0.25 mg ml21) and horseradish-peroxidase-conjugated goat
anti-rabbit antibodies (Amersham), by using the SuperSignal
West Pico enhanced chemiluminescence system (Pierce).
Cell culture, transfection and drug treatments
HeLa and HeLa-Cx26 cells were grown on Dulbecco-modified
Eagle medium supplemented with 10% fetal calf serum, in 5%
CO2 at 378C. Transient transfections were carried out with
Lipofectamine 2000 (Invitrogen). For Golgi-disrupting treat-
ments, cells were incubated at 378C with either 5 mM brefel-
din A (Sigma) for 45 min, or 15 mM nocodazole (Sigma)
for 2 h.
Immunofluorescence
HeLa cells were grown on coverslips, fixed in 4% phosphate-
buffered paraformaldehyde for 15 min at room temperature,
processed for immunofluorescence as described (56), and
imaged in a LSM 510 Meta confocal microscope (Zeiss).
siRNAs and shRNAs
siRNAs targeted the CNST sequences: CNST-826 siRNA
(826–844): 50-CTACGAGAAAGCAATGAAA-30 and CNST-
841 siRNA (841–859): 50-GAAATTCATTCAGCTAGAA-30.
We used siCONTROL (Dharmacon) as non-targeting control
for siRNA experiments. Transfection of 50 nM siRNAs was
carried out with Lipofectamine 2000. Plasmid V2HS_44615
(Open Biosystems), coding for shRNA HP_44254 (57),
targeted CNST sequence 50-GAGGAACTCTGTTAGAATA-30
(2538–2546). Control plasmid encoding a non-silencing
shRNA was also from Open Biosystems. These plasmids were
used to obtain the stable HeLa cell clones HeLa-shRNA-15 and
HeLa RNA-NT, respectively, by transfection and selection in
1 mg ml21 puromycin.
RNA interference assays
RNAi assays were performed in duplicate to assess consortin
protein levels (by immunoblotting) and the effect of consortin
silencing on connexin trafficking (by immunofluorescence).
Transfection of low-passage number (,20) HeLa-shRNA-15
and HeLa RNA-NT cells with either CNST-826, CNST-841
or non-interfering siCONTROL siRNAs was considered the
start point (0 h) of the assay. At 48 h, cells were transfected
with expression plasmids encoding one of the following con-
nexins: Cx26, Cx30 or Cx45-eGFP. Cells were then incubated
for a further 24 h before being processed for either immuno-
blotting or immunofluorescence.
Evaluation of connexin plaques
Cultures of cells transiently expressing different connexins
were grown on coverslips, immunostained for the appropriate
connexin and for Golgi marker GM130, counterstained with
DAPI, and imaged in a LSM 510 Meta confocal microscope
(Zeiss). Bright dots at contacts between adjacent connexin-
expressing cells, as observed in DIC images, were scored as
connexin plaques. Connexin-expressing cells undergoing div-
ision (as shown by DAPI counterstaining) or having a disorga-
nized Golgi apparatus (as indicated by GM130 staining) were
excluded from the counts. The statistical significance of the
results was evaluated with a two-tailed, unpaired t-test with
Welch’s correction (InStat 3.0 software package, GraphPad).
Generation of HeLa cells stably expressing Cx43
Wild-type HeLa cells (33) and the stable HeLa cell clones
HeLa-shRNA-15 and HeLa RNA-NT that were maintained
under 1 mg ml21 puromycin (InvivoGen) selection pressure,
were transfected with the rat Cx43-encoding plasmid G2A
(58) by using either Lipofectamine 2000 (Invitrogen), Poly-
Fect Transfection Reagent (Qiagen) or an MP-100 Micro-
Porator system (Digital Bio), as per the manufacturers’
instructions. Stable transfectants were selected with
350 mg ml21 neomycin (Invitrogen), plus 1 mg ml21 puromy-
cin for double transfectants. These experiments resulted in the
selection of 11, 6 and 10 clones of wild-type, HeLa RNA-NT
and HeLa-shRNA-15 clones, respectively. In each clone, 60–
80% of the cells expressed Cx43, as determined by a 2 h
272 Human Molecular Genetics, 2010, Vol. 19, No. 2
immunolabeling at room temperature of cells permeabilized
for 10 min with 2208C acetone and stained with rabbit poly-
clonal antibodies against Cx43 (71–0700; Zymed), diluted
1:100, and sheep antibodies against rabbit IgGs (1238833,
Boehringer Mannheim), diluted 1:500 (59). Most of the cells
were also positive for consortin, as evaluated by immmunola-
beling with anti-consortin rabbit polyclonal antibody, diluted
1:50 (overnight incubation at 48C of cells fixed in 4% parafor-
maldehyde and permeabilized with 0.1% Triton X-100) and
reacted first with a biotin conjugated goat serum against
rabbit IgGs (111-066-045, Jackson ImmunoResearch),
diluted 1:200, and then with fluorescein-conjugated streptavi-
din (016-090-084, Jackson ImmunoResearch), diluted 1:600.
To minimize the influence of clone-dependent differences,
further experiments were carried out on cell populations
made in equal parts of three to four different clones (one per
transfection procedure) that were pooled for each type of
Cx43-expressing cell.
Immunoelectron microscopy of consortin
HeLa cells were pelleted by centrifugation and fixed in 4%
paraformaldehyde plus 0.1% glutaraldehyde for 5 min at
room temperature, followed by 60 min fixation in 4% parafor-
maldehyde (all fixatives diluted in 0.1 M phosphate buffer, pH
7.4). Cells were washed three times in 0.1 M phosphate buffer,
embedded in 12% gelatin, and cooled on ice. Small blocks of
gelatin-embedded cells were infused with 2.3 M sucrose,
frozen in liquid nitrogen, and sectioned with a EMFCS
cryo-ultramicrotome (Leica). Ultrathin sections were
mounted on Parlodion-coated copper grids. Sections were pro-
cessed and immunolabeled as previously described (60–62),
which included incubations at room temperature with rabbit
anti-consortin polyclonal antibody (diluted 1:1–1:10) for 1–
12 h, and with goat anti-rabbit IgGs antibodies (diluted 1:10)
conjugated to 15-nm gold particles, for 20 min. Labeled sec-
tions were screened and photographed in a CM10 electron
microscope (Philips). Negative controls were run by exposing
the sections only to the gold-conjugated anti-rabbit IgGs anti-
bodies, which did not result in a consistent staining of the
cells.
Immunoelectron microscopy of Cx43
Control and Cx43-expressing HeLa cells were pelleted, fixed,
embedded and mounted as indicated in the previous para-
graph. Ultrathin sections were processed and immunolabeled
as previously described (60–62) which, in these experiments,
included a 1 h exposure at room temperature to either the
rabbit anticonsortin polyclonal antibody (diluted 1:20), or a
rabbit antiCx43 antibody (C6219, Sigma), diluted 1:40 (59).
This incubation was followed by a 20 min exposure at room
temperature to either Protein A-coated 15 nm diameter gold
particles (diluted 1:150) or goat anti rabbit serum
(EM.GAR10, British Biocell International). Cryosections
were screened as mentioned above. Negative controls were
run by exposing the sections only to the Protein A-coated par-
ticles. These incubations did not result in a consistent staining
of the cells (not shown). For evaluation of the labeling distri-
bution, at least 30 cells were screened per group at the original
magnification of 21 000, and the presence of gold particles
on different organelles scored on prints, at the final magnifi-
cation of 63 000. Data on the distribution of gold particles
between compartments were analyzed by chi square tests, as
provided by Statistical Package for Social Sciences (SPSS
Inc.).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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